Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug272 | Ampion Wiki | 0.71 |
| drug3728 | Standard of Care Wiki | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055370 | Lung Injury NIH | 0.19 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
Description: The AUC for OI through 12 hours measured using the trapezoidal method, where OI is defined as mean airway pressure (Paw)×fraction of inspired oxygen (FiO2)×100/arterial pressure of oxygen (PaO2)
Measure: Oxygenation index (OI) area under the curve (AUC)0-12 Time: 12 hours post initiation of dosingDescription: FiO2 change from baseline
Measure: FiO2 Time: 24 hours post initiation of dosingDescription: PaO2 change from baseline
Measure: PaO2 Time: 24 hours post initiation of dosingDescription: SpO2 change from baseline
Measure: Oxygenation from pulse oximetry (SpO2) Time: 24 hours post initiation of dosingDescription: Change from baseline in P/F ratio, defined as PaO2/FiO2
Measure: P/F ratio Time: 24 hours post initiation of dosingDescription: Change from baseline in VI, defined as [respiration rate (RR)×(peak inspriatory pressure [PIP] - peak expiratory end pressure [PEEP])× arterial pressure of carbon dioxide (PaCO2)]/1000
Measure: Ventilation Index (VI) Time: 24 hours post initiation of dosingDescription: Change from baseline in lung compliance, as measured by the ventilator
Measure: Lung compliance Time: 24 hours post initiation of dosingAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports